BioMedTech September 12, 2019 FDA approval to launch a clinical feasibility study in the United States
BioMedTech August 19, 2019 Inclusion of the first patient in Abivax's Phase 2b (ABX464-103) clinical trial for the treatment of hemorrhagic rectocolitis The main evaluation criterion is the reduction of Mayo's score to 8 weeks.
